PF-07245303 is a ITK / TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis [1].
In Vivo, PF-07245303 (2%; topical administration; once daily) significantly reduces oxazolone-induced ear swelling, disease severity scores, and pro-inflammatory cytokine levels in mouse ear tissue, with 43%-61% inhibition of ear thickness observed at multiple time points[1].
In Vitro, PF-07245303 (0.49-40 nM; 60 s association phase, 60-480 s dissociation phase) binds potently to recombinant human ITK, TRKA, TRKB and TRKC proteins, with Kd values of 0.71 nM, 2.94 nM, 8.73 nM and 10 nM, respectively[1]. PF-07245303 potently inhibits the enzymatic activity of full-length human ITK protein under the condition of 1 mM ATP, with an IC50 of 5.62 nM[1]. PF-07245303 (0-10 μM; 30 min pre-incubation, 5 min activation) potently inhibits ITK-dependent PLCγ1 phosphorylation in Jurkat T cells activated by anti-CD3/CD28, with an IC50 of 154 nM[1]. PF-07245303 potently inhibits IL-2 release from human primary CD4+ T cells activated by anti-CD3/CD28, with an IC50 of 38.5 nM[1]. PF-07245303 inhibits IL-2 release from human whole blood T cells activated by anti-CD3/CD28/CD2, with an IC50 of 1350 nM (122 nM after protein binding correction)[1]. PF-07245303 (20-24 h) inhibits the release of IL-4, IL-13, IFNγ, IL-17A and IL-10 from human primary CD4+ T cells activated by anti-CD3/CD28, with corresponding IC50 values of 73.5 nM, 348 nM, 73.2 nM, 282 nM and 114.5 nM[1]. PF-07245303 (6-7 days) inhibits cytokine release from differentiated human Th1, Th2 and Th17 cells, with IC50 values of 35.4 nM, 60.9 nM and 12.5 nM against IFNγ, IL-13 and IL-17A, respectively[1]. PF-07245303 potently inhibits IFNγ release from human primary CD8+ T cells activated by anti-CD3/CD28, with an IC50 of 18.9 nM[1]. PF-07245303 potently inhibits the enzymatic activities of the cytoplasmic domains of human TRKA, TRKB and TRKC, with mean IC50 values of 7.2 nM, 12.0 nM and 20.7 nM, respectively, under 1 mM ATP conditions[1]. PF-07245303 inhibits ligand-induced phosphorylation of human TRKA, TRKB and TRKC in U2OS cells (expressing p75), with IC50 values of 72.6 nM, 48.7 nM and 21.7 nM, respectively[1]. PF-07245303 inhibits NGF-induced activation of primary human blood basophils with an IC50 of 442 nM (39.8 nM after protein binding correction)[1]. PF-07245303 (0.1-10 μM; 24 h IL-4/IL-13 pre-treatment, 5 min NGF co-incubation) inhibits NGF-induced TRKA phosphorylation in human skin explants pre-treated with IL-4/IL-13[1]. PF-07245303 (0.3-10 μM; 24 h) inhibits anti-CD3/CD28-induced IFNG, IL13 and IL2 mRNA expression in a concentration-dependent manner, with almost complete inhibition observed at 10 μM; meanwhile, this agent also suppresses IL-2 protein release, with significant inhibitory effects detected at 1, 3 and 10 μM[1].
References:
[1]. Duffen JL, et al. Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis. Nat Commun. Published online March 9, 2026.
In Vivo, PF-07245303 (2%; topical administration; once daily) significantly reduces oxazolone-induced ear swelling, disease severity scores, and pro-inflammatory cytokine levels in mouse ear tissue, with 43%-61% inhibition of ear thickness observed at multiple time points[1].
In Vitro, PF-07245303 (0.49-40 nM; 60 s association phase, 60-480 s dissociation phase) binds potently to recombinant human ITK, TRKA, TRKB and TRKC proteins, with Kd values of 0.71 nM, 2.94 nM, 8.73 nM and 10 nM, respectively[1]. PF-07245303 potently inhibits the enzymatic activity of full-length human ITK protein under the condition of 1 mM ATP, with an IC50 of 5.62 nM[1]. PF-07245303 (0-10 μM; 30 min pre-incubation, 5 min activation) potently inhibits ITK-dependent PLCγ1 phosphorylation in Jurkat T cells activated by anti-CD3/CD28, with an IC50 of 154 nM[1]. PF-07245303 potently inhibits IL-2 release from human primary CD4+ T cells activated by anti-CD3/CD28, with an IC50 of 38.5 nM[1]. PF-07245303 inhibits IL-2 release from human whole blood T cells activated by anti-CD3/CD28/CD2, with an IC50 of 1350 nM (122 nM after protein binding correction)[1]. PF-07245303 (20-24 h) inhibits the release of IL-4, IL-13, IFNγ, IL-17A and IL-10 from human primary CD4+ T cells activated by anti-CD3/CD28, with corresponding IC50 values of 73.5 nM, 348 nM, 73.2 nM, 282 nM and 114.5 nM[1]. PF-07245303 (6-7 days) inhibits cytokine release from differentiated human Th1, Th2 and Th17 cells, with IC50 values of 35.4 nM, 60.9 nM and 12.5 nM against IFNγ, IL-13 and IL-17A, respectively[1]. PF-07245303 potently inhibits IFNγ release from human primary CD8+ T cells activated by anti-CD3/CD28, with an IC50 of 18.9 nM[1]. PF-07245303 potently inhibits the enzymatic activities of the cytoplasmic domains of human TRKA, TRKB and TRKC, with mean IC50 values of 7.2 nM, 12.0 nM and 20.7 nM, respectively, under 1 mM ATP conditions[1]. PF-07245303 inhibits ligand-induced phosphorylation of human TRKA, TRKB and TRKC in U2OS cells (expressing p75), with IC50 values of 72.6 nM, 48.7 nM and 21.7 nM, respectively[1]. PF-07245303 inhibits NGF-induced activation of primary human blood basophils with an IC50 of 442 nM (39.8 nM after protein binding correction)[1]. PF-07245303 (0.1-10 μM; 24 h IL-4/IL-13 pre-treatment, 5 min NGF co-incubation) inhibits NGF-induced TRKA phosphorylation in human skin explants pre-treated with IL-4/IL-13[1]. PF-07245303 (0.3-10 μM; 24 h) inhibits anti-CD3/CD28-induced IFNG, IL13 and IL2 mRNA expression in a concentration-dependent manner, with almost complete inhibition observed at 10 μM; meanwhile, this agent also suppresses IL-2 protein release, with significant inhibitory effects detected at 1, 3 and 10 μM[1].
References:
[1]. Duffen JL, et al. Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis. Nat Commun. Published online March 9, 2026.